Greenwich LifeSciences, Inc. (GLSI) Income Statement
GLSI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGLSI revenue and net income
GLSI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GLSI quarterly EPS vs estimates
Greenwich LifeSciences beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.34).
GLSI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1,779 | $3,612 | $3,612 | $3,612 | $3,612 | $3,609 | $3,607 | $3,607 | $3,607 |
| Gross profit | −$1,779 | −$3,612 | −$3,612 | −$3,612 | −$3,612 | −$3,609 | −$3,607 | −$3,607 | −$3,607 |
| Research & development | $17.2M | $15.5M | $7.7M | $6.5M | $3.6M | $1.1M | $2.6M | $1.3M | $1.2M |
| Sales, general & admin | $2.2M | $3.1M | $1.6M | $1.6M | $1.0M | $806,188 | $818,887 | $419,639 | — |
| Total operating expenses | $19.4M | $17.6M | $9.3M | $8.0M | $4.6M | $1.9M | $3.4M | $1.7M | $1.6M |
| Operating income | −$19.4M | −$17.6M | −$9.3M | −$8.0M | −$4.6M | −$1.9M | −$3.4M | −$1.7M | −$1.6M |
| Interest income | $89,700 | $223,008 | $450,940 | $215,017 | $27,367 | $832 | — | — | — |
| Interest expense | — | — | — | $215,017 | $27,367 | $0 | $0 | $0 | — |
| Income before taxes | −$19.4M | −$17.4M | −$8.9M | −$7.8M | −$4.6M | −$1.9M | −$3.4M | −$1.7M | −$1.6M |
| Income taxes | — | — | −$2 | −$215,017 | −$27,367 | −$832 | $3 | −$157,534 | $3 |
| Net income | −$19.4M | −$17.4M | −$8.9M | −$7.8M | −$4.6M | −$1.9M | −$3.4M | −$1.7M | −$1.6M |
| EBITDA | −$19.4M | −$17.4M | −$8.9M | −$7.8M | −$4.6M | −$1.9M | −$3.4M | −$1.7M | −$1.6M |
| EPS (diluted) | −$1.43 | −$1.20 | −$0.70 | −$0.61 | −$0.36 | −$0.19 | −$14.25 | −$0.73 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $3,558 | $0 | $0 | $0 | $3,612 | $0 | $0 | $0 | $5,418 | $0 | $0 |
| Cost of revenue | — | $1,779 | — | — | $876 | $903 | — | $903 | $903 | $903 | — | $903 |
| Gross profit | — | $1,779 | — | — | −$876 | −$903 | — | −$903 | −$903 | −$903 | — | −$903 |
| Research & development | $3.6M | $5.2M | $7.6M | $3.5M | $3.5M | $2.3M | $6.2M | $2.3M | $2.3M | $2.2M | $2.3M | $2.2M |
| Sales, general & admin | $462,931 | $518,190 | $355,194 | $653,066 | $538,047 | $681,210 | $1.9M | $437,011 | $354,434 | $343,591 | $503,052 | $344,758 |
| Total operating expenses | $4.0M | $5.7M | $7.9M | $4.2M | $4.0M | $2.8M | $8.1M | $2.7M | $2.7M | $2.5M | $2.8M | $2.5M |
| Operating income | −$4.0M | −$5.7M | −$7.9M | −$4.2M | −$4.0M | −$2.8M | −$8.1M | −$2.7M | −$2.7M | −$2.5M | −$2.8M | −$2.5M |
| Interest income | $72,970 | $68,617 | $22,258 | $22,797 | $20,675 | $23,970 | $43,942 | $60,338 | $54,722 | $64,006 | $89,294 | $111,136 |
| Interest expense | — | — | — | — | — | $223,008 | — | — | — | $116,180 | — | — |
| Income before taxes | −$3.9M | −$5.7M | −$7.9M | −$4.2M | −$4.0M | −$2.7M | −$8.0M | −$2.7M | −$2.6M | −$2.5M | −$2.7M | −$2.4M |
| Income taxes | — | — | — | — | — | $2.5M | — | — | −$3 | −$3 | — | $40,489 |
| Net income | −$3.9M | −$5.7M | −$7.9M | −$4.2M | −$4.0M | −$2.7M | −$8.0M | −$2.7M | −$2.6M | −$2.5M | −$2.7M | −$2.4M |
| EBITDA | −$3.9M | −$5.7M | −$7.9M | −$4.2M | −$4.0M | −$2.7M | — | −$2.7M | −$2.6M | −$2.5M | — | −$2.4M |
| EPS (diluted) | −$0.27 | −$0.39 | −$0.58 | −$0.30 | −$0.30 | −$0.25 | −$0.61 | −$0.20 | −$0.20 | −$0.19 | −$0.21 | −$0.19 |
| Gross margin | — | 50.0% | — | — | — | −25.0% | — | — | — | −16.7% | — | — |
| Operating margin | — | −160,926.2% | — | — | — | −76,654.2% | — | — | — | −46,829.1% | — | — |
| Net margin | — | −158,997.7% | — | — | — | −75,990.6% | — | — | — | −45,647.7% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GLSI's financial statements (latest annual report filed June 1, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GLSI financial results
Greenwich LifeSciences reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $19.4 million. Diluted earnings per share came to −$1.43.
See the GLSI stock overview for the latest quote and news, or the GLSI chart for price history and technical indicators.
GLSI income statement FAQ
Does Greenwich LifeSciences have revenue?
Greenwich LifeSciences reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Greenwich LifeSciences profitable?
No. Greenwich LifeSciences reported a net loss of $19.4 million in fiscal 2025.
How much does Greenwich LifeSciences spend on research and development?
Greenwich LifeSciences spent $17.2 million on research and development in fiscal 2025.
What are Greenwich LifeSciences's earnings per share?
Greenwich LifeSciences earned $-1.43 per diluted share in fiscal 2025, compared with $-1.20 a year earlier.
When will Greenwich LifeSciences report its next earnings?
Greenwich LifeSciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Greenwich LifeSciences's fiscal year end?
Greenwich LifeSciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on June 1, 2026.